249 related articles for article (PubMed ID: 26765682)
1. Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
Bokhorst LP; Lepistö I; Kakehi Y; Bangma CH; Pickles T; Valdagni R; Alberts AR; Semjonow A; Strölin P; Montesino MF; Berge V; Roobol MJ; Rannikko A
BJU Int; 2016 Sep; 118(3):366-71. PubMed ID: 26765682
[TBL] [Abstract][Full Text] [Related]
2. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
3. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
4. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.
Tohi Y; Kato T; Matsumoto R; Shinohara N; Shiga K; Yokomizo A; Nakamura M; Kume H; Mitsuzuka K; Sasaki H; Egawa S; Matsumura M; Hashine K; Inokuchi J; Eto M; Baba H; Ichikawa T; Kinoshita H; Matsuda T; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2020 Dec; 25(12):2107-2114. PubMed ID: 32770439
[TBL] [Abstract][Full Text] [Related]
5. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
[TBL] [Abstract][Full Text] [Related]
6. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
7. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
[TBL] [Abstract][Full Text] [Related]
8. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
9. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
10. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
[TBL] [Abstract][Full Text] [Related]
11. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance.
Ehdaie B; Vertosick E; Spaliviero M; Giallo-Uvino A; Taur Y; O'Sullivan M; Livingston J; Sogani P; Eastham J; Scardino P; Touijer K
J Urol; 2014 Mar; 191(3):660-4. PubMed ID: 24018237
[TBL] [Abstract][Full Text] [Related]
12. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
[TBL] [Abstract][Full Text] [Related]
14. Repeat prostate biopsies predict location of index cancer in an active surveillance cohort.
Tseng KS; Landis P; Brimo F; Partin AW; Epstein JI; Carter HB
BJU Int; 2011 Nov; 108(9):1415-20. PubMed ID: 21443654
[TBL] [Abstract][Full Text] [Related]
15. Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis.
Halpern JA; Sedrakyan A; Dinerman B; Hsu WC; Mao J; Hu JC
J Urol; 2017 Apr; 197(4):1020-1025. PubMed ID: 27856226
[TBL] [Abstract][Full Text] [Related]
16. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
17. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.
Fujita K; Landis P; McNeil BK; Pavlovich CP
J Urol; 2009 Dec; 182(6):2664-9. PubMed ID: 19836757
[TBL] [Abstract][Full Text] [Related]
18. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
19. Is It Time to Revisit the Role of Prostate-specific Antigen Kinetics in Active Surveillance for Prostate Cancer?
Iremashvili V; Kava BR; Manoharan M; Parekh DJ; Punnen S
Urology; 2016 Sep; 95():139-44. PubMed ID: 27130265
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.
Al-Tartir T; Murekeyisoni C; Attwood K; Badkhshan S; Mehedint D; Safwat M; Guru K; Mohler JL; Kauffman EC
J Urol; 2016 Oct; 196(4):1061-8. PubMed ID: 27157375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
